Work over the past SPORE funding period has established the transcription factor MITF as a new melanoma oncogene, and one that represents a promising therapeutic target. We propose here a novel chemical genomic approach toward the development of anti-MITF therapeutics for melanoma. The approach is based on the modulation of gene expression signatures using the Gene Expression-Based High Throughput Screening (GE-HTSO method developed in the Golub laboratory. The expectation is that as a result of this effort, compounds with high potential for clinical translation will be identified. To accomplish these goals, the project has been organized into 3 Specific Aims.
In Aim 1, we will define a gene expression signature of MITF activation through a combination of gain-of-function experiments, loss-of-function experiments (shRNA-mediated), and computational analysis of MITF-associated gene expression patterns in melanoma patient samples. We will then convert that MITF activation signature to a Luminex bead assay (of up to 100 transcripts) that is suitable for high throughput, low cost chemical screening. In parallel, we will evaluate the feasibility of measuring the MITF signature in routinely collected formalin-fixed paraffin-embedded melanoma biopsies such that the MITF signature could serve as a future diagnostic biomarker and pharmacodynamic marker of anti-MITF therapeutic response.
In Aim 2, we will use the MITF signature in a high throughtput screen to identify small molecule compounds capable of modulating the MITF signature, and by inference, capable of modulating MITF activity. Special emphasis will be placed on screening all ~ 2,000 FDAapproved drugs because these can be most rapidly advanced to preclinical and clinical testing. Our experience with other GE-HTS screens is that unexpected activities of FDA-approved compounds are likely to be discovered in this screen.
In Aim 3, we will validate the hits that emerge from the screen, and identify those compounds with the greatest potency, most biological activity in melanoma transformation assays, and as such will prioritize compounds for possible future clinical development.
Showing the most recent 10 out of 132 publications
